Filing Details

Accession Number:
0000899243-22-027462
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-02 18:41:53
Reporting Period:
2022-08-01
Accepted Time:
2022-08-02 18:41:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1878313 Maia Biotechnology Inc. MAIA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1913199 Stan Smith 444 West Lake Street,
Suite 1700
Chicago IL 60606
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-01 200,000 $5.00 496,128 No 4 P Indirect See Footnote
Common Stock Acquisiton 2022-08-01 7,200 $0.00 503,328 No 4 J Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 J Indirect See Footnote
Footnotes
  1. These shares were purchased in the initial public offering (the "IPO") of MAIA Biotechnology, Inc. (the "Issuer"), which closed on August 1, 2022.
  2. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
  3. In connection with a crossover round with certain investors consisting of sales of common stock, $0.0001 par value per share ("Common Stock") of the Issuer at a price of $9.00 per share, in the event that the price per share of Common Stock sold in the IPO was less than $9.00 per share, the Issuer, on the closing date of the IPO (August 1, 2022), issued to such investors, so long as they continued to hold such shares of Common Stock purchased in the crossover round, that number of additional shares of Common Stock such that the price per share they paid in the crossover round was equal to the per share price in the Issuer's IPO. As the reporting person purchased 9,000 shares at $9.00 per share in the crossover round that the reporting person continued to hold, and the per share price in the IPO was $5.00 per share, accordingly, at the close of the IPO, the Issuer issued to the reporting person an additional 7,200 shares of Common Stock for no additional consideration.